4.7 Article

Design, synthesis, biological evaluation, and docking studies of novel (imidazol-5-yl)pyrimidine-based derivatives as dual BRAFV600E/p38α inhibitors

期刊

出版社

ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.ejmech.2021.113277

关键词

BRAF(V600E) Imidazol-5-ylpyrimidine; MAPK14; Melanoma; Molecular docking; TNF-alpha

资金

  1. Korea Institute of Science and Technology (KIST) [2E30341, 2E31130]
  2. National Research Foundation of Korea [2E31130] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)

向作者/读者索取更多资源

The newly synthesized (imidazol-5-yl)pyrimidine compounds exhibited dual inhibitory activity against BRAF(V600E) and p38 alpha kinases, as well as antiproliferative and TNF-alpha inhibitory activities. Compound 20h showed the highest inhibitory activity among the tested compounds.
The synergistic effect of dual inhibition of serine/threonine protein kinases that are involved in the same signalling pathway of the diseases can exert superior biological benefits for treatment of these diseases. In the present work, a new series of (imidazol-5-yl)pyrimidine was designed and synthesized as dual inhibitors of BRAF(V600E) and p38 alpha kinases which are considered as key regulators in mitogen-activated protein kinase (MAPK) signalling pathway. The target compounds were evaluated for dual kinase inhibitory activity. The tested compounds exhibited nanomolar scale IC50 values against BRAF(V600E) and low to sub-micromolar IC50 range against p38 alpha. Compound 20h was identified as the most potent dual BRAF(V600E)/p38 alpha inhibitor with IC50 values of 2.49 and 85 nM, respectively. Further deep investigation revealed that compound 20h possesses inhibitory activity of TNF-alpha production in lipopolysaccharide-induced RAW 264.7 macrophages with IC50 value of 96.3 nM. Additionally, the target compounds efficiently frustrated the proliferation of LOX-IMVI melanoma cell line. Compound 20h showed a satisfactory antiproliferative activity with IC50 value of 13 mu M, while, compound 18f exhibited the highest cytotoxicity potency with IC50 value of 0.9 mu M. Compound 18f is 11.11-fold more selective toward LOX-IMVI melanoma cells than IOSE-80PC normal cells. The newly reported compounds represent therapeutically promising candidates for further development of BRAF(V600E)/p38 alpha inhibitors in an attempt to overcome the acquired resistance of BRAF mutant melanoma. (c) 2021 Elsevier Masson SAS. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据